Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Valeant Pharma (VRX) Enters Information Sharing Agreement with Pershing Square
March 23, 2016 4:37 PM EDTPershing Square filed an amended 13D on Valeant Pharma (NYSE: VRX) today. The following letter was disclosed:
Dear Mr. Pearson:
I am delighted to join the Valeant Pharmaceuticals International, Inc. (Valeant) board, and I look forward to making a contribution to the company.
This letter, intended solely for the benefit of Valeant, contains a series of undertakings by myself, my firm and the investment funds that we advise (collectively, Pershing Square or we). The undertakings in the following two paragraphs of this letter will be effective so long as the confidential... More
